{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1381699996301072641.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Dieter Depisch"}],"foaf:familyName":[{"@value":"Depisch"}],"foaf:givenName":[{"@value":"Dieter"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1361699996301072640","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1002/1097-0142(20000601)88:11<2505::aid-cncr11>3.0.co;2-e"},{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(20000601)88:11%3C2505::AID-CNCR11%3E3.0.CO;2-E"},{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(20000601)88:11%3C2505::AID-CNCR11%3E3.0.CO;2-E"}],"notation":[{"@value":"A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/1097-0142(20000601)88:11<2505::aid-cncr11>3.0.co;2-e_BY7mUXhBKLAr7FWpT2yHqmSiiin"}]}